Navigation Links
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Date:11/15/2007

Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions

BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. The Phase 1 study, which was conducted in normal volunteers, has shown good tolerance with oral bioavailability of the active ingredient, and an excellent safety profile without serious adverse reactions. The findings were released in an abstract published in the proceedings of the upcoming annual meeting of the American Society of Hematology.

G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection). Ganite(R) is marketed by Genta and approved in the U.S. for treatment of cancer-related hypercalcemia that is resistant to hydration. Low doses of the active ingredient in Ganite administered by intravenous or subcutaneous injections have shown clinical activity in a range of skeletal diseases, including hypercalcemia, bone metastasis (myeloma and breast cancer), Paget's disease, and osteoporosis.

The initial clinical trial was a Phase 1 study of escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and to assess pharmacokinetics and oral bioavailability. The drug was tested over a dosing range of the active ingredient from 30 to 150 mg, and no adverse effects attributable to G4544 were observed in this study. Initial analysis of plasma samples of low doses sh
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the ... announces the following financial results for its third quarter of ... 30, 2014: , Revenue of $1,291,378, a 13% ... , Net loss for the quarter of $240,156 compared to ... prior year For the nine months ended ...
(Date:8/27/2014)... 27, 2014  After the February 2014 launch of ... solution for medical practices and management companies, Prime ... new software. "The feedback has been great," ... "The sheer number of demos and new sign-ups is ... for these types of software features." ...
(Date:8/27/2014)... , Aug. 27, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , today announced the results of the Company,s ... 2014 in Beijing , PRC. The required quorum, ... The Company,s shareholders approved the following proposals:  ... Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... derivative compound series,show highly selective PI3K-inhibition which ... 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris,Inc. , ... on,endocrine therapy and oncology, today presented an ... pyridopyrazine derivatives,with high selectivity for PI3K inhibition, ...
... With Improved Potential to,Battle Their Disease, PASADENA, ... Inc., a majority-owned subsidiary of Arrowhead,Research Corporation ... will be featured in a poster presentation ... (AACR) Annual,Meeting. In particular, this poster includes ...
Cached Medicine Technology:AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
(Date:8/27/2014)... last time you experienced worrisome medical symptoms, did ... health-care professional? If so, you,re not alone. Consumers ... peer support groups to gather anecdotal information and ... and trustworthy sources. New research to be presented ... studies the characteristics of consumers who use the ...
(Date:8/27/2014)... August 27, 2014 Will Holbrook, CP ... Will has over 15 years of experience in ... in Rome, Georgia with a Bachelor of Science degree ... chemistry. He received his graduate degree in prosthetics ... excited to have Will join us at Fourroux,” says ...
(Date:8/27/2014)... -- In a new study done from the heights ... pressure steadily increases if you ascend to great heights. ... to treat high blood pressure was ineffective once climbers ... online Aug. 27 in the European Heart Journal ... at sea level who have sleep apnea, in which ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... enhancement and protection services for hospitals, is pleased to ... Inc. 5000 List of America’s Fastest-Growing Companies. The list ... of the economy—America’s independent entrepreneurs. , "It's been ... honored to be included in this year's Inc. 5000 ...
(Date:8/27/2014)... 2014 The American Brain Tumor ... the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant ... ABTA is seeding the field with talented, bright young ... of the causes, effects, diagnosis and treatment of brain ... committee based on the potential to advance the understanding ...
Breaking Medicine News(10 mins):Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3
... the tourist resort city of Livingstone were tested for bird ... backyards'. // ,Simon Miti, the permanent secretary at ... thorough investigation of the outbreak'. ,The number of ... residents who cooked and ate the dead chickens have been ...
... is found to enhance educational achievements and combat other behavioral ... that it has a positive effect on the kids suffering ... responded better to Omega 3 fish oils than to the ... found that fish oil is very essential for the kids. ...
... the killer of Lin and Megan Russell has petitioned the High ... public since it would be misused by the press. ... committed a decade ago. Stone's lawyer, Richard Clayton QC said that ... be seriously misused by the tabloid press. ,Mr Clayton ...
... Delhi Police summoned three doctors of the Indraprastha Apollo ... //on the condition of Rahul Mahajan, who was admitted ... overdose. ,"We have summoned the doctors and ... of police, heading the probe against the hospital. ...
... introduce a common school system in the country, educationists ... the primary education //system and remove disparities among students. ... school system in the country so that all students ... students," said Madhu Prasad, educationist and a professor in ...
... According to a new study published in the Journal ... epileptic seizures by inducing rhythmical //electrical activity in the ... the hippocampus. The researchers found that, by imposing a ... reduce epileptic seizures by 86-97%. ,The study ...
Cached Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: